Why do the Goal Posts Keep Moving: What is the Correct Target in IBD Treatment?

08/16/2018

Related Content

Gastroenterology

Therapeutic Drug Monitoring is NOT Needed for anti-TNF Therapy

08/01/2018

Immunology

08/03/2017

Rachael Buck, PhD, discusses the potential of a new infant formula she and her research team developed, which harnesses the unique qualities and benefits of human milk oligosaccharides (an alternative...

08/03/2017

Influenza

Gustavo Ferrer, MD, FCCP, on Combining Conventional Medicine with Holistic Remedies May Produce Synergies

06/29/2018

Gustavo Ferrer, MD, FCCP, discusses the occasions when traditional remedies like garlic and chicken soup might help boost the immune system in patients with the flu.

06/29/2018

Gastroenterology

Gastroenterology

How can we better prevent and treat narcotic dependence in our pediatric IBD patients?

08/15/2018

Gastroenterology

Adherence Issues in IBD

08/17/2018

Current Consultant Issue

Previous Issues

Early View

Research Summaries

Research Summary

Research Summary

Phase 3 ROSELLA Shows OS Gain in Platinum-Resistant Ovarian Cancer

05/14/2026

Ashton L. Stahl

Phase 3 data evaluated whether relacorilant plus nab-paclitaxel improves survival in platinum-resistant ovarian cancer.

05/14/2026

Long COVID Roundup

Long COVID Roundup

Studies Associate Long COVID With Cognitive, Neurologic, and Academic Outcomes

05/14/2026

Anthony Calabro, MA

Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms. ...

05/14/2026

Research Summary

Research Summary

Phase 2 MRD-Driven Acalabrutinib Triplets Show Molecular Complete Responses in Frontline MCL

05/14/2026

Anthony Calabro, MA

In an open-label, multicenter phase 2 study, frontline mantle cell lymphoma, MRD-driven acalabrutinib-lenalidomide anti-CD20 therapy produced high molecular complete response rates.

05/14/2026

Research Summary

doctor with clipboard talking to patient

Research Summary

Phase 1/2 BRUIN: Pirtobrutinib Maintains Patient-Reported Outcomes in CLL/SLL and MCL

05/14/2026

Anthony Calabro, MA

In phase 1/2 BRUIN, most patients with CLL/SLL or MCL had stable or improved PROs during pirtobrutinib treatment.

05/14/2026

FDA Approval

FDA Approval

FDA Grants Accelerated Approval to Sonrotoclax (Beqalzi) for Relapsed or Refractory MCL

05/14/2026

Ashton L. Stahl

The FDA has approved sonrotoclax for adults with relapsed or refractory mantle cell lymphoma who have received prior BTK inhibitor therapy.

05/14/2026

Trending Articles

Disease State Pillar

Disease State Pillar

HIV Management: A Practical Guide for Primary Care

12/09/2025

With modern antiretroviral therapy (ART), human immunodeficiency virus (HIV) is a chronic, manageable condition—but outcomes hinge on rapid treatment start, durable viral suppression, and proactive primary...

12/09/2025

Disease State Pillar

Disease State Pillar

Chronic Obstructive Pulmonary Disease: A Comprehensive Guide for Primary Care

11/05/2025

What is COPD? Chronic obstructive pulmonary disease (COPD) is a progressive, preventable condition marked by airflow limitation and respiratory symptoms such as dyspnea, chronic cough, and sputum...

11/05/2025

Disease State Pillar

Disease State Pillar

Agitation in Alzheimer Disease: A Comprehensive Guide for Primary Care

09/08/2025

Agitation is a common and challenging behavioral symptom in dementia that primary care providers frequently encounter. Characterized by increased motor activity, restlessness, verbal or physical aggression,...

09/08/2025

Slideshow

Slideshow

Consultant360’s Summer Playlist: Expert Perspectives on Emerging Clinical Issues

09/15/2025

This summer, Consultant360 brought you thought-provoking conversations with leading clinicians on some of the most pressing issues in patient care—from the latest Advisory Committee on Immunization...

09/15/2025

Meeting Coverage

Meeting Coverage

What Clinicians Need to Know About ACIP’s June 2025 Meeting

09/26/2025

Key Highlights Clesrovimab approved for infants under 8 months to prevent respiratory syncytial virus during their first season, and added to the Vaccines for Children program for free access. FluMist...

09/26/2025